As on Wednesday, Pyxis Oncology Inc (NASDAQ: PYXS) got off with the flyer as it spiked 1.39% to $3.66, before settling in for the price of $3.61 at the close. Taking a more long-term approach, PYXS posted a 52-week range of $1.35-$6.85.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 0.00% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -118.72%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 45.05%. This publicly-traded company’s shares outstanding now amounts to $59.42 million, simultaneously with a float of $46.71 million. The organization now has a market capitalization sitting at $217.48 million. At the time of writing, stock’s 50-day Moving Average stood at $3.55, while the 200-day Moving Average is $3.76.
Pyxis Oncology Inc (PYXS) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Pyxis Oncology Inc’s current insider ownership accounts for 21.40%, in contrast to 52.35% institutional ownership. According to the most recent insider trade that took place on Sep 28 ’23, this organization’s CFO and COO bought 8,000 shares at the rate of 1.87, making the entire transaction reach 14,960 in total value, affecting insider ownership by 818,532. Preceding that transaction, on Sep 27 ’23, Company’s Chief Accounting Officer bought 2,500 for 1.87, making the whole transaction’s value amount to 4,675. This particular insider is now the holder of 226,937 in total.
Pyxis Oncology Inc (PYXS) Earnings and Revenue Records
Pyxis Oncology Inc’s EPS increase for this current 12-month fiscal period is 45.05% and is forecasted to reach -1.17 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 34.60% through the next 5 years, which can be compared against the -118.72% growth it accomplished over the previous five years trading on the market.
Pyxis Oncology Inc (NASDAQ: PYXS) Trading Performance Indicators
Let’s observe the current performance indicators for Pyxis Oncology Inc (PYXS). It’s Quick Ratio in the last reported quarter now stands at 9.53. The Stock has managed to achieve an average true range (ATR) of 0.21. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 13.47.
In the same vein, PYXS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.26, a figure that is expected to reach -0.32 in the next quarter, and analysts are predicting that it will be -1.17 at the market close of one year from today.
Technical Analysis of Pyxis Oncology Inc (PYXS)
Through scrutinizing the latest numbers posted by the [Pyxis Oncology Inc, PYXS], it can be observed that its last 5-days Average volume of 0.5 million was lower the volume of 0.64 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 47.85% While, its Average True Range was 0.20.
Raw Stochastic average of Pyxis Oncology Inc (PYXS) in the period of the previous 100 days is set at 43.15%, which indicates a major fall in contrast to 54.46% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 61.92% that was lower than 61.98% volatility it exhibited in the past 100-days period.
